SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Rule 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
October 4, 2018
Zymeworks Inc.
(Exact name of registrant as specified in its charter)
|
British Columbia, Canada
|
001-38068
|
47-2569713
|
|
(State or other jurisdiction
of incorporation)
|
(Commission File Number)
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
Suite 540, 1385 West 8th Avenue, Vancouver, British Columbia, Canada
|
V6H 3V9
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
|
(604) 678-1388
|
|
|
|
(Registrant’s telephone number, including area code)
|
||
|
Not Applicable
|
||
|
(Former name of former address, if changed since last report)
|
||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☑
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☑
| ITEM 8.01 |
OTHER EVENTS
|
The following information is filed pursuant to Item 8.01, “Other Events.”
On October 4, 2018, Zymeworks Inc. announced that it will webcast its R&D Briefing from 9:00 a.m. to 12:00 p.m. Eastern Time on Thursday, October 11, 2018 in New York City.
| ITEM 9.01 |
FINANCIAL STATEMENTS AND EXHIBITS
|
(d) Exhibits
|
Exhibit No.
|
Description
|
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
ZYMEWORKS INC.
|
|||||
|
(Registrant)
|
|||||
|
Date: October 4, 2018
|
By:
|
/s/ Neil Klompas
|
|||
|
Name:
|
Neil Klompas
|
||||
|
Title:
|
Chief Financial Officer
|
||||
Exhibit 99.1
Zymeworks to Webcast R&D Briefing
Vancouver, Canada (October 4, 2018) – Zymeworks Inc. (NYSE/TSX: ZYME), a clinical‑stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that it will webcast its R&D Briefing from 9:00 a.m. to 12:00 p.m. Eastern Time on Thursday, October 11, 2018 in New York City.
Zymeworks’ management team will discuss the Company’s clinical strategy for ZW25, provide an update on its next clinical compound ZW49, and highlight its early-stage platforms and technologies.
The management team will be joined by two prominent clinical oncologists:
| · |
Mark Pegram, MD, is the Susy Yuan-Huey Hung Professor of Medicine (Oncology) at the Stanford University Medical Center, Director of the Stanford Cancer Institute's Breast Oncology Program, Associate Director of Clinical Research, and Associate Dean of Clinical Research Quality. Dr. Pegram played a significant role in the development of Herceptin for the treatment of HER2- positive breast cancer.
|
| · |
Elena Elimova, MD, MSc, is a medical oncologist at the Princess Margaret Hospital in Toronto where she serves as an Assistant Professor within the Department of Medicine, Division of Medical Oncology at the University of Toronto. Dr. Elimova specializes in the treatment of patients with gastroesophageal cancers. Her primary area of research is concentrated on the care of patients with gastroesophageal malignancies and the development of novel biomarkers, which can predict response to therapy.
|
Webcast
The live audio webcast and slide presentation for the event may be accessed via a link from Zymeworks’ website at http://ir.zymeworks.com/events-and-presentations, which will also host a recorded replay available following the event.
About Zymeworks Inc.
Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of next-generation multifunctional biotherapeutics. Zymeworks’ suite of complementary therapeutic platforms and its fully-integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly-differentiated product candidates. Zymeworks’ lead product candidate, ZW25, is a novel bispecific antibody currently being evaluated in an adaptive Phase 1 clinical trial. Zymeworks is also advancing a deep pipeline of preclinical product candidates and discovery-stage programs in immuno-oncology and other therapeutic areas. In addition to Zymeworks’ wholly-owned pipeline, its therapeutic platforms have been further leveraged through multiple strategic partnerships with global biopharmaceutical companies.
For more information, visit us online at www.zymeworks.com.
Contacts:
Zymeworks Inc.
Investor Inquiries:
Ryan Dercho, Ph.D.
(604) 678-1388
ir@zymeworks.com
Media Inquiries:
Angela Bitting
(925) 202-6211
a.bitting@comcast.net